News
Crossfire Oncology unveils degrader-based payload and presents best-in-class macrocyclic BTK inhibitor CFON-026 at AACR 2024
Oss, 19 April 2024
The Crossfire team attended this year’s American Association for Cancer Research (AACR) annual meeting with three posters. On Tuesday the Crossfire team unveiled its highly innovative degrader-based payload targeting an essential cell cycle kinase. Its sophisticated design is expected to
Crossfire Oncology to present best-in-class macrocyclic BTK inhibitor CFON-026 and novel Degrader Antibody Conjugate technology at AACR 2024
Oss, 19 February 2024
The Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) annual meeting 2024. We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our
Crossfire enters state-of-the-art laboratories at the Marie Curie Building (Pivot Park)
Oss, 5 February 2024
Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs)